@article{oldfield_experiences_2020,
	title = {Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of {New} {Zealand} doctors in an oncology setting},
	issn = {0032-5473, 1469-0756},
	url = {https://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2020-139013},
	doi = {10.1136/postgradmedj-2020-139013},
	abstract = {Purpose of Study
              To explore the experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in New Zealand doctors in an oncology setting.
            
            
              Study Design
              An observational cross-sectional survey undertaken between November 2019 and January 2020 across four secondary-care hospital oncology departments within New Zealand (Auckland, Wellington, Christchurch and Dunedin). Participants were a convenience sample of doctors; consultants, registrars, medical officers of special status and house surgeons working in oncology departments. Of 53 individuals approached, 45 participated (85\% Response Rate). The primary outcome was reporteddoctor-patient interactions. Secondary outcomes included knowledge of cannabis-based products, their efficacy, prescribing regulations and educational access.
            
            
              Results
              Of 44 doctors, 37 (84\%, 95\% CI: 70 to 93) reported patient requests to prescribe cannabis-based products and 43 (98\%, 95\% CI: 88 to 100) reported patients using illicit cannabis for medical symptoms. Primary request reasons were pain, nausea/vomiting and cancer treatment. 33/45 (73\%, 95\% CI: 58 to 85) cited knowledge of at least one cannabis-based product and 27/45 (60\%, 95\% CI: 44 to 74) indicated at least one condition that had evidence of efficacy. 36/44 (82\%, 95\% CI: 67 to 92) expressed future prescribing concerns but all were willing to use a cannabis-based product developed with traditional medical provenance.
            
            
              Conclusion
              In the oncology setting, patients are asking doctors about symptomatic and curative treatment with cannabis-based products. Doctors are not biased against the use of products showing medical provenance; however, NZ-specific clinical and regulatory guidelines are essential to support patient discussions and appropriate prescribing.},
	language = {en},
	urldate = {2021-06-08},
	journal = {Postgraduate Medical Journal},
	author = {Oldfield, Karen and Eathorne, Allie and Tewhaiti-Smith, Jordan and Beasley, Richard and Semprini, Alex and Braithwaite, Irene},
	month = nov,
	year = {2020},
	pages = {postgradmedj--2020--139013},
}

{"_id":"yxgNQrGFzrHyRoPKe","bibbaseid":"oldfield-eathorne-tewhaitismith-beasley-semprini-braithwaite-experiencespatientinteractionsandknowledgeregardingtheuseofcannabisasamedicineinacohortofnewzealanddoctorsinanoncologysetting-2020","author_short":["Oldfield, K.","Eathorne, A.","Tewhaiti-Smith, J.","Beasley, R.","Semprini, A.","Braithwaite, I."],"bibdata":{"bibtype":"article","type":"article","title":"Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of New Zealand doctors in an oncology setting","issn":"0032-5473, 1469-0756","url":"https://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2020-139013","doi":"10.1136/postgradmedj-2020-139013","abstract":"Purpose of Study To explore the experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in New Zealand doctors in an oncology setting. Study Design An observational cross-sectional survey undertaken between November 2019 and January 2020 across four secondary-care hospital oncology departments within New Zealand (Auckland, Wellington, Christchurch and Dunedin). Participants were a convenience sample of doctors; consultants, registrars, medical officers of special status and house surgeons working in oncology departments. Of 53 individuals approached, 45 participated (85% Response Rate). The primary outcome was reporteddoctor-patient interactions. Secondary outcomes included knowledge of cannabis-based products, their efficacy, prescribing regulations and educational access. Results Of 44 doctors, 37 (84%, 95% CI: 70 to 93) reported patient requests to prescribe cannabis-based products and 43 (98%, 95% CI: 88 to 100) reported patients using illicit cannabis for medical symptoms. Primary request reasons were pain, nausea/vomiting and cancer treatment. 33/45 (73%, 95% CI: 58 to 85) cited knowledge of at least one cannabis-based product and 27/45 (60%, 95% CI: 44 to 74) indicated at least one condition that had evidence of efficacy. 36/44 (82%, 95% CI: 67 to 92) expressed future prescribing concerns but all were willing to use a cannabis-based product developed with traditional medical provenance. Conclusion In the oncology setting, patients are asking doctors about symptomatic and curative treatment with cannabis-based products. Doctors are not biased against the use of products showing medical provenance; however, NZ-specific clinical and regulatory guidelines are essential to support patient discussions and appropriate prescribing.","language":"en","urldate":"2021-06-08","journal":"Postgraduate Medical Journal","author":[{"propositions":[],"lastnames":["Oldfield"],"firstnames":["Karen"],"suffixes":[]},{"propositions":[],"lastnames":["Eathorne"],"firstnames":["Allie"],"suffixes":[]},{"propositions":[],"lastnames":["Tewhaiti-Smith"],"firstnames":["Jordan"],"suffixes":[]},{"propositions":[],"lastnames":["Beasley"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Semprini"],"firstnames":["Alex"],"suffixes":[]},{"propositions":[],"lastnames":["Braithwaite"],"firstnames":["Irene"],"suffixes":[]}],"month":"November","year":"2020","pages":"postgradmedj–2020–139013","bibtex":"@article{oldfield_experiences_2020,\n\ttitle = {Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of {New} {Zealand} doctors in an oncology setting},\n\tissn = {0032-5473, 1469-0756},\n\turl = {https://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2020-139013},\n\tdoi = {10.1136/postgradmedj-2020-139013},\n\tabstract = {Purpose of Study\n To explore the experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in New Zealand doctors in an oncology setting.\n \n \n Study Design\n An observational cross-sectional survey undertaken between November 2019 and January 2020 across four secondary-care hospital oncology departments within New Zealand (Auckland, Wellington, Christchurch and Dunedin). Participants were a convenience sample of doctors; consultants, registrars, medical officers of special status and house surgeons working in oncology departments. Of 53 individuals approached, 45 participated (85\\% Response Rate). The primary outcome was reporteddoctor-patient interactions. Secondary outcomes included knowledge of cannabis-based products, their efficacy, prescribing regulations and educational access.\n \n \n Results\n Of 44 doctors, 37 (84\\%, 95\\% CI: 70 to 93) reported patient requests to prescribe cannabis-based products and 43 (98\\%, 95\\% CI: 88 to 100) reported patients using illicit cannabis for medical symptoms. Primary request reasons were pain, nausea/vomiting and cancer treatment. 33/45 (73\\%, 95\\% CI: 58 to 85) cited knowledge of at least one cannabis-based product and 27/45 (60\\%, 95\\% CI: 44 to 74) indicated at least one condition that had evidence of efficacy. 36/44 (82\\%, 95\\% CI: 67 to 92) expressed future prescribing concerns but all were willing to use a cannabis-based product developed with traditional medical provenance.\n \n \n Conclusion\n In the oncology setting, patients are asking doctors about symptomatic and curative treatment with cannabis-based products. Doctors are not biased against the use of products showing medical provenance; however, NZ-specific clinical and regulatory guidelines are essential to support patient discussions and appropriate prescribing.},\n\tlanguage = {en},\n\turldate = {2021-06-08},\n\tjournal = {Postgraduate Medical Journal},\n\tauthor = {Oldfield, Karen and Eathorne, Allie and Tewhaiti-Smith, Jordan and Beasley, Richard and Semprini, Alex and Braithwaite, Irene},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {postgradmedj--2020--139013},\n}\n\n","author_short":["Oldfield, K.","Eathorne, A.","Tewhaiti-Smith, J.","Beasley, R.","Semprini, A.","Braithwaite, I."],"key":"oldfield_experiences_2020","id":"oldfield_experiences_2020","bibbaseid":"oldfield-eathorne-tewhaitismith-beasley-semprini-braithwaite-experiencespatientinteractionsandknowledgeregardingtheuseofcannabisasamedicineinacohortofnewzealanddoctorsinanoncologysetting-2020","role":"author","urls":{"Paper":"https://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2020-139013"},"metadata":{"authorlinks":{}},"downloads":1},"bibtype":"article","biburl":"https://api.zotero.org/users/6607533/collections/TJPQG7MU/items?key=hSjrOPQRRHHWY81SKs6CEz45&format=bibtex&limit=100","dataSources":["2RD657JdK4hka2DeP","x3a5YBvn82E6RBLXv","CfMcCM7QT97iZEsTA","rhgC4BmfWie6Lm3F7"],"keywords":[],"search_terms":["experiences","patient","interactions","knowledge","regarding","use","cannabis","medicine","cohort","new","zealand","doctors","oncology","setting","oldfield","eathorne","tewhaiti-smith","beasley","semprini","braithwaite"],"title":"Experiences, patient interactions and knowledge regarding the use of cannabis as a medicine in a cohort of New Zealand doctors in an oncology setting","year":2020,"downloads":1}